J. Goldman & CO LP Actinium Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.39 $205,405 - $269,755	-28,728 Reduced 68.03%	13,500 $100,000
Q1 2023 May 15, 2023	SELL	$8.51 - $14.26 $322,358 - $540,168	-37,880 Reduced 47.29%	42,228 $399,000
Q4 2022 Feb 14, 2023	SELL	$9.71 - $12.51 $666,397 - $858,561	-68,630 Reduced 46.14%	80,108 $853,000
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $715,429 - $1.26 Million	148,738 New	148,738 $1.1 Million
Q4 2020 Feb 16, 2021	SELL	$7.8 - $12.64 $1.32 Million - $2.13 Million	-168,749 Closed	0 $0

Q3 2020 Nov 16, 2020	BUY	$7.26 - $18.0 $1.23 Million - $3.04 Million	168,749 New	168,749 $1.64 Million

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.